Amgen’s ABP980, a biosimilar of Genentech's cancer treatment Herceptin, was denied approval by the U.S. Food and Drug Administration, the company announced June 1. The Thousand Oaks biotech giant said it received a complete response letter from the FDA. The letters are sent out if the agency has decided not to approve a drug, containing…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
